ProCE Banner Activity

Expert Commentary on the Use of IL-13 Inhibition in Treating Moderate to Severe Atopic Dermatitis

Clinical Thought

In this commentary, Dr Jonathan Silverberg provides insights on incorporating IL-13 inhibitors into the treatment algorithm for moderate to severe atopic dermatitis.

Released: May 19, 2023

Share

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly